Bone Marrow Transplantation News

The Fred Hutchinson Cancer Research Center announced the official opening of a first-of-its-kind clinic dedicated to providing cellular-based immunotherapies for patients with cancer.

SAN DIEGO — Ibrutinib safely and effectively treated patients with chronic graft-versus-host disease who failed at least one line of systemic therapy, according to a late-breaking abstract presented at the ASH Annual Meeting and Exposition.

SAN DIEGO — Saad Z. Usmani, MD, FACP, director of plasma cell disorders and director of clinical research in the department of hematologic malignancies at Levine Cancer Institute at Carolinas HealthCare System, spoke with HemOnc Today at the ASH Annual Meeting and Exposition about the impact of the results from the STAMINA trial.

ASH selected 20 junior medical educators to participate in its ASH Medical Educators Institute.

SAN DIEGO — Ibrutinib conferred clinically meaningful and durable responses in a cohort of patients with chronic graft-versus-host disease who had failed after corticosteroids, according to findings presented during the late-breaking abstract session of the ASH Annual Meeting and Exposition.

SAN DIEGO — The use of matched sibling peripheral blood stem cell and bone marrow grafts led to faster engraftment and a reduction in transplant-related mortality compared with matched sibling cord blood and bone marrow grafts in patients with thalassemia major, according to results of a prospective, single-center trial presented at the ASH Annual Meeting and Exposition.

Hematopoietic stem cell transplantation survivors experience significantly greater rates of hospitalization and mortality from all causes years after their transplants than cancer survivors who did not undergo HSCT, according to a comparative study published in Journal of Clinical Oncology.

SAN DIEGO — Patients with mantle cell lymphoma who underwent autologous hematopoietic stem cell transplantation experienced improved EFS with periodic rituximab maintenance therapy, according to findings of the phase 3 LyMa trial presented at the ASH Annual Meeting and Exposition.

SAN DIEGO — Oral vancomycin, a standard antibiotic, effectively prevented Clostridium difficile infection in patients undergoing allogeneic hematopoietic stem cell transplantation, according to study results presented at the ASH Annual Meeting and Exposition.

SAN DIEGO — CPX-351 conferred better outcomes after allogeneic hematopoietic stem cell transplantation than standard cytarabine and daunorubicin in older patients with high-risk acute myeloid leukemia, according to results of an exploratory analysis of a phase 3 trial presented at the ASH Annual Meeting and Exposition.